Companies - A
Addgene Non-profit organization working with hundreds of laboratories to assemble a high-quality library of published plasmids for use in research and discovery. By linking plasmids with articles, scientists can always find data related to the materials they request. |
|
Advanced Cell & Gene Therapy, LLC Consulting firm in cell therapy, gene therapy and tissue therapies, serving biotechnology companies, clinical laboratories, and biotechnology investors. |
|
Advanced Vision Therapies, Inc. Gene transfer technology for the treatment of eye diseases like Wet Age-Related Macular Degeneration (AMD), Diabetic Proliferative Retinopathy (DPR), Retinitis Pigmentosa (RP) and Dry Age-Related Macular Degeneration. |
|
AlphaVax Human Vaccines, Inc. AlphaVax is developing a new vaccine technology, alphavaccines, with broad applications against cancer and infectious disease, like pandemic influenza and cytomegalovirus. |
|
Altogen Biosystems Life sciences company dedicated to the development, marketing and manufacture of cell line specific transfection reagents for intracellular delivery of biomolecules (siRNA and plasmid DNA). |
|
American Gene Technologies Gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications. The company expects its lead candidate for an HIV cure to enter the clinic in 2018, and it has developed a patented immuno-oncology approach to attack a variety of epithelial cancers that is expected to enter trials soon. |
|
Applied Tissue Technologies LLC Technologies focus on direct methods of treating infection in skin wounds, transplanting skin to wounds, and delivering genes to skin cells. |
|
Ark Therapeutics Ltd. Gene therapy company focuses on areas of high unmet clinical need in vascular disease, wound care and cancer. Products in late stage clinical development: Cerepro®, Vitor™ and Trinam® |
|
Arthrogen An Amsterdam based clinical stage, biopharmaceutical company, is developing local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases. Currently two phase Ib trials are ongoing, one in Canada and one in the Netherlands. |
|
Asklepios BioPharmaceutical Inc. Biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of Biological Nano Particles (BNP). BNPs are synthetically designed from components of different Adeno Associated Viruses as well as other parvoviruses. |
|
Athersys, Inc. Clinical stage biopharmaceutical company with lead programs in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support. |
|
Austrianova Focused on the development and manufacture of highly innovative tumour treatments based on localized cell therapies. Reference product NovaCaps® is the first encapsulated cell product targeting solid tumours. |
|